The abstract is read at the publisher; the summary is JClub's.
In 46 first-line metastatic pancreatic ductal adenocarcinoma patients, the ICSBR regimen achieved a 78.3% 6-month progression-free survival rate, exceeding the 60% target.
- Why it matters: Outcomes for metastatic pancreatic ductal adenocarcinoma remain poor, and better first-line strategies are needed, alongside biomarkers to guide precision treatment.
- What they did: In this multicenter, single-arm phase II trial (ChiCTR2300073237), patients received serplulimab plus gemcitabine/nab-paclitaxel in 21-day cycles with stereotactic body radiotherapy during cycle 2, plus comprehensive biomarker analysis.
- The result: Median progression-free survival was 8.5 months and median overall survival was 14.0 months (not reached), with a 73.9% objective response rate and no treatment-related deaths; ctDNA negativity and tumor microenvironment features were linked to outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.